Does the media prefer IMMX or FHTX?

In the previous week, Immix Biopharma had 4 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 25 mentions for Immix Biopharma and 21 mentions for Foghorn Therapeutics. Immix Biopharma's average media sentiment score of 0.37 beat Foghorn Therapeutics' score of -0.50 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 6 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media refer more to AVTX or FHTX?

In the previous week, Foghorn Therapeutics had 18 more articles in the media than Avalo Therapeutics. MarketBeat recorded 21 mentions for Foghorn Therapeutics and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.11 beat Foghorn Therapeutics' score of -0.50 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media refer more to FDMT or FHTX?

In the previous week, Foghorn Therapeutics had 18 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 21 mentions for Foghorn Therapeutics and 3 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.31 beat Foghorn Therapeutics' score of -0.50 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media prefer GERN or FHTX?

In the previous week, Foghorn Therapeutics had 20 more articles in the media than Geron. MarketBeat recorded 21 mentions for Foghorn Therapeutics and 1 mentions for Geron. Geron's average media sentiment score of 1.54 beat Foghorn Therapeutics' score of -0.50 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Foghorn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media refer more to SLDB or FHTX?

In the previous week, Foghorn Therapeutics had 19 more articles in the media than Solid Biosciences. MarketBeat recorded 21 mentions for Foghorn Therapeutics and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.25 beat Foghorn Therapeutics' score of -0.50 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Neutral

Foghorn Therapeutics (FHTX) Competitors

$2.00 -0.02 (-0.99%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$2.02 +0.02 (+0.75%)

As of 07:02 AM Eastern

Compare

FHTX vs. IMMX, AVTX, FDMT, GERN, and SLDB

Should you buy Foghorn Therapeutics stock or one of its competitors? Foghorn Therapeutics's main competitors and comparable companies include Immix Biopharma (IMMX), Avalo Therapeutics (AVTX), 4D Molecular Therapeutics (FDMT), Geron (GERN), and Solid Biosciences (SLDB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Foghorn Therapeutics compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Immix Biopharma has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

Immix Biopharma has higher earnings, but lower revenue than Foghorn Therapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
Foghorn Therapeutics	$30.91M	3.84	-$74.28M	-$0.98	N/A

In the previous week, Immix Biopharma had 4 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 25 mentions for Immix Biopharma and 21 mentions for Foghorn Therapeutics. Immix Biopharma's average media sentiment score of 0.37 beat Foghorn Therapeutics' score of -0.50 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	6 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Neutral

Immix Biopharma presently has a consensus price target of $24.14, suggesting a potential upside of 138.33%. Foghorn Therapeutics has a consensus price target of $6.67, suggesting a potential upside of 233.33%. Given Foghorn Therapeutics' higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Foghorn Therapeutics	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Immix Biopharma has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the broader market.

Summary

Immix Biopharma beats Foghorn Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Avalo Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

In the previous week, Foghorn Therapeutics had 18 more articles in the media than Avalo Therapeutics. MarketBeat recorded 21 mentions for Foghorn Therapeutics and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.11 beat Foghorn Therapeutics' score of -0.50 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Neutral

Avalo Therapeutics currently has a consensus target price of $45.10, indicating a potential upside of 208.90%. Foghorn Therapeutics has a consensus target price of $6.67, indicating a potential upside of 233.33%. Given Foghorn Therapeutics' higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Foghorn Therapeutics	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Foghorn Therapeutics has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	13,049.97	-$78.26M	-$4.37	N/A
Foghorn Therapeutics	$30.91M	3.84	-$74.28M	-$0.98	N/A

Avalo Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Foghorn Therapeutics beats Avalo Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Foghorn Therapeutics has a net margin of -175.78% compared to 4D Molecular Therapeutics' net margin of -194.74%. Foghorn Therapeutics' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

In the previous week, Foghorn Therapeutics had 18 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 21 mentions for Foghorn Therapeutics and 3 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.31 beat Foghorn Therapeutics' score of -0.50 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Neutral

4D Molecular Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Foghorn Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.38	-$140.11M	-$2.63	N/A
Foghorn Therapeutics	$30.91M	3.84	-$74.28M	-$0.98	N/A

4D Molecular Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 124.46%. Foghorn Therapeutics has a consensus target price of $6.67, indicating a potential upside of 233.33%. Given Foghorn Therapeutics' higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Foghorn Therapeutics	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Summary

Foghorn Therapeutics beats 4D Molecular Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Geron?

Geron (NASDAQ:GERN) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Geron currently has a consensus target price of $4.00, suggesting a potential upside of 230.58%. Foghorn Therapeutics has a consensus target price of $6.67, suggesting a potential upside of 233.33%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Foghorn Therapeutics	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Foghorn Therapeutics has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.23	-$83.50M	-$0.11	N/A
Foghorn Therapeutics	$30.91M	3.84	-$74.28M	-$0.98	N/A

73.7% of Geron shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Foghorn Therapeutics had 20 more articles in the media than Geron. MarketBeat recorded 21 mentions for Foghorn Therapeutics and 1 mentions for Geron. Geron's average media sentiment score of 1.54 beat Foghorn Therapeutics' score of -0.50 indicating that Geron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Foghorn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Neutral

Geron has a net margin of -34.17% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

Geron has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market.

Summary

Foghorn Therapeutics beats Geron on 9 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Foghorn Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Foghorn Therapeutics	$30.91M	3.84	-$74.28M	-$0.98	N/A

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Solid Biosciences presently has a consensus price target of $18.69, suggesting a potential upside of 164.76%. Foghorn Therapeutics has a consensus price target of $6.67, suggesting a potential upside of 233.33%. Given Foghorn Therapeutics' higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Foghorn Therapeutics	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Solid Biosciences has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the broader market.

In the previous week, Foghorn Therapeutics had 19 more articles in the media than Solid Biosciences. MarketBeat recorded 21 mentions for Foghorn Therapeutics and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.25 beat Foghorn Therapeutics' score of -0.50 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Neutral

Solid Biosciences has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

Summary

Foghorn Therapeutics beats Solid Biosciences on 10 of the 15 factors compared between the two stocks.

Get Foghorn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FHTX vs. The Competition

Export

Metric	Foghorn Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$119.96M	$3.85B	$7.14B	$13.26B
Dividend Yield	N/A	3.65%	2.54%	17.37%
P/E Ratio	-2.04	12.99	274.34	26.20
Price / Sales	3.84	1,189.99	577.41	78.74
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	-1.04	16.96	11.20	6.40
Net Income	-$74.28M	-$23.20M	$3.49B	$381.07M
7 Day Performance	-43.18%	-2.19%	-1.37%	-0.30%
1 Month Performance	-59.35%	-10.27%	-6.02%	-4.53%
1 Year Performance	-55.85%	17.40%	7.24%	1.62%

Foghorn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FHTX Foghorn Therapeutics	2.3067 of 5 stars	$2.00 -1.0%	$6.67 +233.3%	-56.9%	$118.77M	$36.74M	N/A	106	Analyst Revision
IMMX Immix Biopharma	3.1035 of 5 stars	$10.54 -8.1%	$24.14 +129.1%	+391.7%	$820.56M	N/A	N/A	21	High Trading Volume
AVTX Avalo Therapeutics	2.249 of 5 stars	$15.58 +3.3%	$45.10 +189.5%	+9.0%	$808.74M	$60K	N/A	33
FDMT 4D Molecular Therapeutics	2.6062 of 5 stars	$14.49 -0.5%	$29.00 +100.1%	+51.1%	$804.36M	$85.21M	N/A	196	News Coverage
GERN Geron	2.2378 of 5 stars	$1.24 -0.8%	$4.00 +222.6%	-10.4%	$803.09M	$183.88M	N/A	258

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FHTX) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. IMMX, AVTX, FDMT, GERN, and SLDB

How does Foghorn Therapeutics compare to Immix Biopharma?

Summary

How does Foghorn Therapeutics compare to Avalo Therapeutics?

Summary

How does Foghorn Therapeutics compare to 4D Molecular Therapeutics?

Summary

How does Foghorn Therapeutics compare to Geron?

Summary

How does Foghorn Therapeutics compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. IMMX, AVTX, FDMT, GERN, and SLDB

How does Foghorn Therapeutics compare to Immix Biopharma?

Is IMMX or FHTX more profitable?

Which has preferable valuation & earnings, IMMX or FHTX?

Does the media prefer IMMX or FHTX?

Do analysts rate IMMX or FHTX?

Do insiders and institutionals hold more shares of IMMX or FHTX?

Which has more risk and volatility, IMMX or FHTX?

Summary

How does Foghorn Therapeutics compare to Avalo Therapeutics?

Is AVTX or FHTX more profitable?

Does the media refer more to AVTX or FHTX?

Do analysts prefer AVTX or FHTX?

Which has stronger earnings & valuation, AVTX or FHTX?

Which has more volatility & risk, AVTX or FHTX?

Do insiders & institutionals believe in AVTX or FHTX?

Summary

How does Foghorn Therapeutics compare to 4D Molecular Therapeutics?

Is FDMT or FHTX more profitable?

Does the media refer more to FDMT or FHTX?

Which has more volatility & risk, FDMT or FHTX?

Do institutionals and insiders have more ownership in FDMT or FHTX?

Which has stronger valuation and earnings, FDMT or FHTX?

Do analysts rate FDMT or FHTX?

Summary

How does Foghorn Therapeutics compare to Geron?

Do analysts recommend GERN or FHTX?

Which has better earnings and valuation, GERN or FHTX?

Do insiders & institutionals hold more shares of GERN or FHTX?

Does the media prefer GERN or FHTX?

Is GERN or FHTX more profitable?

Which has more volatility and risk, GERN or FHTX?

Summary

How does Foghorn Therapeutics compare to Solid Biosciences?

Which has preferable earnings and valuation, SLDB or FHTX?

Do insiders & institutionals hold more shares of SLDB or FHTX?

Do analysts rate SLDB or FHTX?

Which has more risk & volatility, SLDB or FHTX?

Does the media refer more to SLDB or FHTX?

Is SLDB or FHTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools